Researchers achieved a breakthrough by keeping a sliver of the mammalian cochlea alive outside the body, directly revealing the biomechanics of hearing and opening new avenues to treat sensorineural hearing loss.
In a study reported December 14 in the journal “Nature Communications,” researchers led by McGovern Institute for Brain Research associate investigator Josh McDermott used computational modeling to explore factors that influence how humans hear pitch.
George Cire, Chris James, and Paula Greenham review the major treatment modalities, the general indications for implant use and referral, and present a picture of current clinical practice as reflected in Cochlear Ltd’s Implant Recipient Observational Study (IROS).
Researchers at Uppsala University have created the “first 3D map of the hearing nerve showing where the various sound frequencies are captured,” according to an article on the university’s website. Using what is known as synchrotron X-ray imaging, they were able to trace the fine nerve threads and the vibrating auditory organ, the cochlea, and find out exactly how the frequencies of incoming sound are distributed.
Read More
Cooling the sensitive tissues of the inner ear before and during a cochlear implant surgery may lead to better hearing outcomes, according to a University of Miami Health System and College of Engineering researcher who is leading a collaborative team developing this therapeutic approach.
Read More
The data show hearing improvements in adults with acquired sensorineural hearing loss (SNHL) and the “first known linkage of pharmacokinetics and pharmacodynamics for a potential hearing restoration therapy,” according to Frequency.
Read More
We hear sounds in part because tiny filaments inside our inner ears help convert voices, music, and noises into electrical signals that are sent to our brains for processing. Now, scientists have mapped and simulated those filaments at the atomic level, a discovery that shed lights on how the inner ear works and that could help researchers learn more about how and why people lose the ability to hear.
Read More
At the end of two weeks, results showed that for the COVID-infected group, high-frequency pure-tone thresholds as well as the TEOAE amplitudes were significantly worse in the test group, indicating damage to outer ear hair cells.
Read More
Vertidiag is said to have developed a technical platform to induce controlled vestibular disorders and to measure their functional impacts. This platform uses behavioral pharmacology, along with a battery of cellular and molecular biology tools that support the understanding of the mechanisms of action of potential drug candidates.
Read More
FX-322 is Frequency’s lead product candidate, designed to regenerate auditory sensory hair cells in the cochlea and improve hearing in patients with sensorineural hearing loss (SNHL).
Read More
Cochlear Limited (ASX: COH), a company that specializes in implantable hearing solutions,...
Read More
Todays more competitive hearing care market makes it especially critical for practices to establish strong relationships with local physicians and heathcare providers.
Read More
Cochlear Limited (ASX: COH), an implantable hearing solutions company, announced the US Food and...
Read More
Using zebrafish as a proxy, scientists have shed light on how changes to specific genes alter the coordinated direction that these cells are laid out.
Read More
In a Phase 1/2 study, FX-322 demonstrated a statistically significant and clinically meaningful improvement in key measures of hearing loss, including clarity of sound and word recognition, with no serious adverse events observed.
Read More
Nearly 24% of US adults ages 20 to 69 have features of their hearing tests in one or both ears that suggest hearing loss from loud noise, based on a 2017 study by researchers from the NIDCD and the Centers for Disease Control and Prevention (CDC).
Read More
The new technology is based on a recent hearing aid specification, Audio Streaming for Hearing Aids (ASHA) on Bluetooth Low Energy Connection-Oriented Channels, which Google has developed in collaboration with GN Hearing and Cochlear.
Read MoreThese funds will enable Strekin to conclude its ongoing Phase 3 clinical trial of STR001 in Sudden Sensorineural Hearing Loss, the RESTORE trial, and to prepare for a European filing.
Read More